Correlative studies in neuro-oncology trials: Should they influence treatment?

Current Oncology Reports

Volumn 8, Issue 1, 2006, Pages 54-57

  Hegi, Monika E ^a   Stupp, Roger ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; DNA; EPIDERMAL GROWTH FACTOR; LOMUSTINE; MITOGEN ACTIVATED PROTEIN KINASE 13; MOLECULAR MARKER; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG EFFICACY; DRUG TARGETING; GENE DELETION; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMAN; METHODOLOGY; OBSERVER VARIATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROMOTER REGION; PROTEIN TARGETING; RADIATION HAZARD; REVIEW; SIDE EFFECT; STANDARDIZATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

BRAIN NEOPLASMS; CLINICAL TRIALS; FEMALE; GLIOMA; HUMANS; MALE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 31544435155     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0010-z     Document Type: Review

References (38)

1. Godard S, Getz G, Delorenzi M, et al.: Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003, 63:6613-6625.
2. Misra A, Pellarin M, Nigro J, et al.: Array comparative gemomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 2005, 11:2907-2918.
3. Watanabe K, Tachibana O, Sata K, et al.: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996, 6:217-223; discussion 223-214.
4. Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479.
5. Smith JS, Perry A, Borell TJ, et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636-645.
6. Cairncross G, Seiferheld W, Shaw E, et al.: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004, 22 (14S): abstract 1500.
7. van den Bent MJ, Delattre J-Y, Brandes AA, et al.: First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. J Clin Oncol 2005, 23(16 Suppl):114s [abstract 1503].
8. Burger PC: What is an oligodendroglioma? Brain Pathol 2002, 12:257-259.
9. Choe G, Horvath S, Cloughesy TF, et al.: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003, 63:2742-2746.
10. Montgomery RB, Moscatello DK, Wong AJ, et al.: Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 1995, 270:30562-30566.
11. Guha A, Feldkamp MM, Lau N, et al.: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997, 15:2755-2765.
12. Rajasekhar VK, Viale A, Socci ND, et al.: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003, 12:889-901.
13. Moscatello DK, Holgado-Madruga M, Emlet DR, et al.: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998, 273:200-206.
14. Rich JN, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
15. Haas-Kogan DA, Prados MD, Tihan T, et al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97:880-887.
16. Cappuzzo F: Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J Natl Cancer Inst 2005, 97:868-869.
17. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
18. Paez JG, Janne PA, Lee JC, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
19. Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000, 60:1383-1387.
20. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004, 351:2883.
21. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
22. Lachat Y, Diserens AC, Nozaki M, et al.: INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma. Oncogene 2004, 23:6854-6863.
23. Gondar RK, Shi Q, Hjelmeland MD, et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005, 4:101-112.
24. Beuvink I, Boulay A, Fumagalli S, et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
25. Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
26. Hegi ME, Diserens A-C, Godard S, et al.: Clinical trial substantiates the predictive value of MGMT-methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
27. Stupp R, Dietrich P-Y, Ostermann Kraljevic S, et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382.
28. Hotta T, Saito Y, Fujita H, et al.: O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21:135-140.
29. Belanich M, Pastor M, Randall T, et al.: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996, 56:783-788.
30. Jaeckle KA, Eyre HJ, Townsend JJ, et al.: Correlation of tumor 06 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16:3310-3315.
31. Friedman HS, McLendon RE, Kerby T, et al.: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16:3851-3857.
32. Silber JR, Blank A, Bobola MS, et al.: O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999, 5:807-814.
33. Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4:296-307.
34. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
35. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
36. DeAngelis LM: Chemotherapy for brain tumors: a new beginning. N Engl J Med 2005, 352:1036-1038.
37. Wasserfallen JB, Ostermann S, Pica A, et al.: Can we afford to add chemotherapy to radiotherapy for glioblastoma. multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer 2004, 101:2098-2105.
38. Mollemann M, Wolter M, Felsberg J, et al.: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005, 113:379-385.